FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012908535> ?p ?o ?g. }

• W2012908535 endingPage "146" @default.
• W2012908535 startingPage "141" @default.
• W2012908535 abstract "Objective To evaluate the efficacy and toxicity of erlotinib in the management of squamous cell carcinoma (SCC) of the vulva. Methods Patients with vulvar lesions amenable to surgery or chemoradiation (cohort 1) or those with metastatic measurable disease (cohort 2) received erlotinib 150 mg daily. Patients were monitored for toxicity. Responses were determined by digital photography or RECIST 1.1. Cohort 1 underwent pre and post treatment biopsies. EGFR immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and mutational analysis were performed. Results 41 patients were enrolled: 17 in cohort 1 and 24 in cohort 2. Notable grade 3 or 4 toxicities included allergic reaction (1), diarrhea/electrolyte abnormalities (3), ischemic colitis (1), and renal failure (3) and electrolyte abnormalities (n=2). Mean number of cycles for cohort 2 was 3.3. Overall clinical benefit rate was 67.5% with 11 (27.5%) partial responses (PR), 16 (40.0%) stable disease (SD), and 7 (17.5%) progressive disease. Responses were of short duration. All pre and post treatment biopsies exhibited 2–3+ EGFR staining. 5 of 14 patients (35%) were found to have EGFR amplification (n=3) or high polysomy/trisomy (n=2). These five patients had either a PR (n=3) or SD (n=2). Gain of function mutations were not been identified. Conclusions This is the first reported controlled trial evaluating erlotinib for the management of vulvar carcinoma. Toxicities were acceptable given the lack of treatment options for these patients. Given the observed clinical benefits erlotinib may represent one of the most active agents available to treat vulvar SCC." @default.
• W2012908535 created "2016-06-24" @default.
• W2012908535 creator A5005661299 @default.
• W2012908535 creator A5030257115 @default.
• W2012908535 creator A5031431934 @default.
• W2012908535 creator A5040266917 @default.
• W2012908535 creator A5057700449 @default.
• W2012908535 creator A5058249824 @default.
• W2012908535 creator A5059711716 @default.
• W2012908535 creator A5060473465 @default.
• W2012908535 creator A5082822346 @default.
• W2012908535 creator A5089158382 @default.
• W2012908535 date "2012-10-01" @default.
• W2012908535 modified "2023-10-18" @default.
• W2012908535 title "Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva" @default.
• W2012908535 cites W1983277106 @default.
• W2012908535 cites W1992523140 @default.
• W2012908535 cites W2005823843 @default.
• W2012908535 cites W2005943756 @default.
• W2012908535 cites W2024111812 @default.
• W2012908535 cites W2028256854 @default.
• W2012908535 cites W2036754281 @default.
• W2012908535 cites W2048113480 @default.
• W2012908535 cites W2056370053 @default.
• W2012908535 cites W2059780149 @default.
• W2012908535 cites W2059958002 @default.
• W2012908535 cites W2070773043 @default.
• W2012908535 cites W2071819298 @default.
• W2012908535 cites W2078879168 @default.
• W2012908535 cites W2084196799 @default.
• W2012908535 cites W2093426923 @default.
• W2012908535 cites W2095148478 @default.
• W2012908535 cites W2096322101 @default.
• W2012908535 cites W2097196133 @default.
• W2012908535 cites W2098073930 @default.
• W2012908535 cites W2101329867 @default.
• W2012908535 cites W2101995865 @default.
• W2012908535 cites W2105834225 @default.
• W2012908535 cites W2109897091 @default.
• W2012908535 cites W2122885616 @default.
• W2012908535 cites W2139819066 @default.
• W2012908535 cites W2148783573 @default.
• W2012908535 cites W2149412903 @default.
• W2012908535 cites W2156508041 @default.
• W2012908535 cites W2157824687 @default.
• W2012908535 cites W2165119042 @default.
• W2012908535 cites W2227527565 @default.
• W2012908535 doi "https://doi.org/10.1016/j.ygyno.2012.06.028" @default.
• W2012908535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22750258" @default.
• W2012908535 hasPublicationYear "2012" @default.
• W2012908535 type Work @default.
• W2012908535 sameAs 2012908535 @default.
• W2012908535 citedByCount "68" @default.
• W2012908535 countsByYear W20129085352012 @default.
• W2012908535 countsByYear W20129085352013 @default.
• W2012908535 countsByYear W20129085352014 @default.
• W2012908535 countsByYear W20129085352015 @default.
• W2012908535 countsByYear W20129085352016 @default.
• W2012908535 countsByYear W20129085352017 @default.
• W2012908535 countsByYear W20129085352018 @default.
• W2012908535 countsByYear W20129085352019 @default.
• W2012908535 countsByYear W20129085352020 @default.
• W2012908535 countsByYear W20129085352021 @default.
• W2012908535 countsByYear W20129085352022 @default.
• W2012908535 countsByYear W20129085352023 @default.
• W2012908535 crossrefType "journal-article" @default.
• W2012908535 hasAuthorship W2012908535A5005661299 @default.
• W2012908535 hasAuthorship W2012908535A5030257115 @default.
• W2012908535 hasAuthorship W2012908535A5031431934 @default.
• W2012908535 hasAuthorship W2012908535A5040266917 @default.
• W2012908535 hasAuthorship W2012908535A5057700449 @default.
• W2012908535 hasAuthorship W2012908535A5058249824 @default.
• W2012908535 hasAuthorship W2012908535A5059711716 @default.
• W2012908535 hasAuthorship W2012908535A5060473465 @default.
• W2012908535 hasAuthorship W2012908535A5082822346 @default.
• W2012908535 hasAuthorship W2012908535A5089158382 @default.
• W2012908535 hasConcept C121608353 @default.
• W2012908535 hasConcept C126322002 @default.
• W2012908535 hasConcept C141071460 @default.
• W2012908535 hasConcept C143998085 @default.
• W2012908535 hasConcept C2776316342 @default.
• W2012908535 hasConcept C2778087573 @default.
• W2012908535 hasConcept C2779438470 @default.
• W2012908535 hasConcept C71924100 @default.
• W2012908535 hasConcept C72563966 @default.
• W2012908535 hasConcept C90924648 @default.
• W2012908535 hasConceptScore W2012908535C121608353 @default.
• W2012908535 hasConceptScore W2012908535C126322002 @default.
• W2012908535 hasConceptScore W2012908535C141071460 @default.
• W2012908535 hasConceptScore W2012908535C143998085 @default.
• W2012908535 hasConceptScore W2012908535C2776316342 @default.
• W2012908535 hasConceptScore W2012908535C2778087573 @default.
• W2012908535 hasConceptScore W2012908535C2779438470 @default.
• W2012908535 hasConceptScore W2012908535C71924100 @default.
• W2012908535 hasConceptScore W2012908535C72563966 @default.
• W2012908535 hasConceptScore W2012908535C90924648 @default.
• W2012908535 hasIssue "1" @default.
• W2012908535 hasLocation W20129085351 @default.

• next